ENDRA Life Sciences Inc.
NDRA Healthcare Diagnostics & Research
In the quarter to June 2026, EPS grew 107.0% and free cash flow grew 15.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow NDRA
ENDRA Life Sciences Inc. (NDRA) Piotroski F-score
ENDRA Life Sciences Inc.'s Piotroski F-score for fiscal 2018 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2018 | 6 | — |
How fiscal 2018’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (146.80%) | (162.58%) | Fail | 0 |
| Positive operating cash flow | (7.70m) | (3.30m) | Fail | 0 |
| Rising return on assets | (146.80%) | (162.58%) | Pass | 1 |
| Cash flow above net income | 2.09m | 2.08m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 7.13 | 6.93 | Pass | 1 |
| No new shares issued | 100 | 100 | Pass | 1 |
| Rising gross margin | 100.00% | 50.85% | Pass | 1 |
| Rising asset turnover | 0.00 | 0.11 | Fail | 0 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| NDRA ENDRA Life Sciences Inc. | 6 |
| PMD Psychemedics Corporation compare | 5 |
| NOTVQ Inotiv, Inc. compare | 5 |
| ISPC iSpecimen Inc. compare | 3 |
| XWEL XWELL, Inc. compare | 3 |
| DMTKQ DermTech, Inc. compare | 3 |
| BIAF bioAffinity Technologies, Inc. compare | 2 |
| TTOO T2 Biosystems, Inc. compare | 2 |
| ADVB Advanced Biomed Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover